Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 SeverityArticle Published on 2022-08-292022-11-15 Journal: Neurology® neuroimmunology & neuroinflammation [Category] 바이오마커, 진단, [키워드] 95% CI Acetate acute respiratory syndrome adjusted Admission age anti-CD20 artificial ventilation association Clinical characteristics Comprehensive coronavirus coronavirus disease country Course COVID-19 COVID-19 severity death Effects Factor Hospitalization Infection intensive care International Logistic regression Male sex medication multiple sclerosis Older age Other outcome Patient patients phenotype predicted Probability real-world data Result severe COVID-19 severity Sex therapy Ventilation were assessed with COVID-19 [DOI] 10.1212/NXI.0000000000200021 PMC 바로가기
Resurgence of Influenza Circulation in the Russian Federation during the Delta and Omicron COVID-19 EraArticle Published on 2022-08-292022-11-15 Journal: Viruses [Category] SARS, 신종인플루엔자, 치료기술, [키워드] Acute respiratory infection antigenic antigenic properties antivirals ARI baseline circulating circulation clade COVID-19 Delta epidemiological European Federation genetic analysis homogenous Hospitalization ILI incidence Influenza influenza B influenza epidemic influenza viruses Intervention Lineage majority NGS NGS sequencing NPI NPIs omicron other respiratory virus PCR reduced reservoirs respiratory viruses resurgence Russia SARS-CoV-2 Surveillance susceptibility susceptibility to antivirals. the epidemic the vaccine Victoria lineage Virological virus [DOI] 10.3390/v14091909 PMC 바로가기
Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana projectArticle Published on 2022-08-292022-11-15 Journal: Frontiers in Immunology [Category] 진단, [키워드] adverse event age and sex analyzed anti-SARS-CoV-2 baseline Biomarker booster dose ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine chemiluminescence chemokines Concentration Controlled trial COVID-19 Cytokines death dose effective Effectiveness evaluated exclusion first dose Fractional dose Frequency geometric mean Growth factors healthcare worker Hospitalization immune response immunization immunoassay immunogenic immunogenicity incidence incidence rate increase in indicate individual individuals multiplex neutralizing antibody non-inferiority non-randomized plaque reduction neutralization plasma pre-immune primary endpoint PRNT Protein quantified RBD Receptor binding domain Registered reported RT-PCR Safe Safety second dose Serious Adverse Event seroconversion rate seronegative seropositive seropositive subject SUS Vaccine Vaccines [DOI] 10.3389/fimmu.2022.966416 PMC 바로가기
Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance – COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022Article Published on 2022-08-262022-11-16 Journal: Morbidity and Mortality Weekly Report [Category] SARS, 변종, [키워드] Adults analyzed booster cause circulating COVID-19 doses high risk Hospitalization Hospitalized measure network nonpregnant omicron Patient predominant PROTECT SARS-CoV-2 sequenced severe COVID-19 illness The United States vaccination variant variant of SARS-CoV-2 virus Weekly with COVID-19 [DOI] 10.15585/mmwr.mm7134a3 PMC 바로가기
Effects of lymphocyte and neutrophil counts and their time courses on mortality in patients with postoperative pneumonia Research Published on 2022-08-262022-10-05 Journal: Scientific Reports [Category] 바이오마커, [키워드] Absolute lymphocyte count absolute neutrophil count ALC analyzed ANC change characteristic community-acquired pneumonia Course Diagnosis difference Effect evaluate evaluated feature highlight Hospitalization immunological increase in information lymphocyte lymphopenia Mortality neutrophil neutrophil count non-survivor Patient patients Pneumonia post-hoc analysis postoperative prognostic prognostic effect Prognostic factor Prolonged prospective observational study Research severe lymphopenia single-center survival survival rate survivor were assessed [DOI] 10.1038/s41598-022-18794-5 [Article Type] Research
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLLArticle Published on 2022-08-262022-11-15 Journal: Journal of Hematology & Oncology [Category] SARS, 진단, [키워드] 95%CI Admission advanced age affected age albumin Analysis anticoagulation therapy bleeding C-reactive protein CLL Complication conducted COVID-19 COVID-19 diagnosis D-dimer Data collection death deficiency defined development dose administration ENhance European event high risk Hospitalization Hospitalized ICU immune increased risk initiative leukemia LMWH Most patient multivariate model nasal Occurrence outcomes oxygen oxygen supplementation Patient peak D-dimer pharyngeal polymerase chain presence of comorbidities Prognostic factor prophylactic dose Protective receiving recommendation reported Retrospective multicenter study risk RT-PCR SARS-CoV-2 severe COVID-19 severity STROBE susceptible swabs the disease Thromboembolic event Thromboprophylaxis thrombosis Thrombotic events Treatment treatment for COVID-19 were used [DOI] 10.1186/s13045-022-01333-0 PMC 바로가기
Epstein-Barr Virus and Human Herpesvirus-6 Reactivation in Acute COVID-19 PatientsArticle Published on 2022-08-252022-11-15 Journal: Viruses [Category] 치료기술, [키워드] Activation association Autoimmune disorders blood donor Characteristics Coagulopathies Cohort cohorts complex contribute COVID-19 COVID-19 patient detectable disease EBV Epstein-Barr virus Epstein–Barr virus feature fraction Frequency healthy healthy control herpesvirus HHV-6 Hospitalization Hospitalized Human Human Herpesvirus-6 hyperinflammatory responses Infection Inflammation Inflammatory inflammatory disease Inflammatory mediators marker occurred Pathogenesis Patient patients plasma pulmonary disease quantitative PCR Reactivation reported SARS-CoV-2 subset syndrome tested virus with COVID-19 [DOI] 10.3390/v14091872 PMC 바로가기
Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant periodArticle Published on 2022-08-252022-11-15 Journal: Frontiers in Immunology [Category] 진단, [키워드] 95%CI absence analyzed Angiotensin-converting enzyme angiotensin-converting enzyme inhibitor angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers ARBs blocker Care CCI Charlson comobidity index clinician Comorbidity Coronavirus disease 2019 COVID-19 COVID-19 patient cut-off value died discharged dominant echocardiographic Endpoint greater help high-risk patient Hospital admission Hospitalization Hospitalized hospitalized COVID-19 patient hospitalized patient in-hospital mortality Infection inhibitor Laboratory laboratory-confirmed males Mortality mortality risk Neutrophil-to-lymphocyte ratio NLR Older omicron Patient physical predict predicted predictor Prevalence prognostic indicator Radiographic receptor reduce risk stratification significantly the primary endpoint therapy [DOI] 10.3389/fimmu.2022.958418 PMC 바로가기
Necessity of Coronavirus Disease 2019 (COVID-19) Vaccination in Persons Who Have Already Had COVID-19이미 COVID-19에 걸린 사람에 대한 코로나바이러스 질병 2019(COVID-19) 예방 접종의 필요성Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] 95% CI Cleveland clinic coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination Cox proportional hazard cumulative incidence demonstrated employee evaluate examined group groups Hospitalization hospitalizations Immunity incidence infected individual Infection lower risk mRNA vaccine multivariable Not demonstrated omicron Omicron variant Person positive provide receiving remained risk risk of COVID-19 SARS-CoV-2 second dose significantly lower subjects symptomatic symptomatic COVID-19 tested uninfected vaccination Vaccines variant [DOI] 10.1093/cid/ciac022 PMC 바로가기 [Article Type] Article
Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study코로나바이러스 질병 2019(COVID-19) 환자 치료를 위한 렘데시비르 플러스 덱사메타손 대 덱사메타손 단독 요법: 보충 O2 요법이 필요한 환자: 전향적 통제된 비무작위 연구Controlled Clinical Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, 치료제, [키워드] 30-Day mortality Antiviral baseline calculated clinical outcomes cohorts Combination Controlled coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient CRP D-dimer Dexamethasone drug effective Endpoint enrolled evaluate evaluated faster fibrinogen FiO2 group groups Hospitalization IMPROVE independent Inflammatory inflammatory markers Kaplan-Meier Kaplan-Meier curve Kaplan-Meier curves laboratory characteristics log-rank test median Mortality neutrophil neutrophil/lymphocyte ratio no differences occurred primary endpoint primary endpoints Prospective reducing mortality reduction in reduction in mortality Remdesivir Respiratory failure Respiratory function Sample size SARS-CoV-2 clearance secondary Secondary endpoints shown significant difference significant differences survival the log-rank test therapy treat Treatment viral clearance were used [DOI] 10.1093/cid/ciac014 PMC 바로가기 [Article Type] Controlled Clinical Trial